NEW
YORK, Aug. 6, 2024 /PRNewswire/ -- The global
colorectal cancer therapeutics market size is estimated to grow by
USD 2.00 billion from 2024-2028,
according to Technavio. The market is estimated to grow at a CAGR
of 4.5% during the forecast period. Increasing
geriatric population is driving market growth, with a
trend towards development of small molecule kinase inhibitors.
However, patent expiration of novel therapeutics poses a
challenge. Key market players include Accord Healthcare Ltd., Amgen
Inc., Amneal Pharmaceuticals Inc., Bayer AG, Biocon Ltd., Bristol
Myers Squibb Co., CK Hutchison Holdings Ltd., Eli Lilly and Co., F.
Hoffmann La Roche Ltd., Fresenius SE and Co. KGaA, Hetero Drugs
Ltd., Hikma Pharmaceuticals Plc, Merck and Co. Inc., Ono
Pharmaceutical Co. Ltd., Otsuka Holdings Co. Ltd., Pfizer Inc.,
Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical
Industries Ltd., and Viatris Inc..
![Technavio has announced its latest market research report titled Global colorectal cancer therapeutics market 2024-2028 Technavio has announced its latest market research report titled Global colorectal cancer therapeutics market 2024-2028](https://mma.prnewswire.com/media/2475464/Technavio_Global_colorectal_cancer_therapeutics_market_2024_2028.jpg)
Get a detailed analysis on regions, market
segments, customer landscape, and companies- View the
snapshot of this report
Colorectal Cancer
Therapeutics Market Scope
|
Report
Coverage
|
Details
|
Base year
|
2023
|
Historic
period
|
2018 - 2022
|
Forecast
period
|
2024-2028
|
Growth momentum &
CAGR
|
Accelerate at a CAGR of
4.5%
|
Market growth
2024-2028
|
USD 2001.8
million
|
Market
structure
|
Fragmented
|
YoY growth 2022-2023
(%)
|
4.23
|
Regional
analysis
|
North America, Europe,
Asia, and Rest of World (ROW)
|
Performing market
contribution
|
North America at
44%
|
Key
countries
|
US, Germany, UK,
Canada, and China
|
Key companies
profiled
|
Accord Healthcare Ltd.,
Amgen Inc., Amneal Pharmaceuticals Inc., Bayer AG, Biocon Ltd.,
Bristol Myers Squibb Co., CK Hutchison Holdings Ltd., Eli Lilly and
Co., F. Hoffmann La Roche Ltd., Fresenius SE and Co. KGaA, Hetero
Drugs Ltd., Hikma Pharmaceuticals Plc, Merck and Co. Inc., Ono
Pharmaceutical Co. Ltd., Otsuka Holdings Co. Ltd., Pfizer Inc.,
Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical
Industries Ltd., and Viatris Inc.
|
Market Driver
The colorectal cancer therapeutics market is currently dominated
by biologics, but their high development costs, complex processes,
and associated side effects are limiting their adoption. In
response, pharmaceutical companies are focusing on creating safe,
affordable, and easy-to-administer small molecule drugs. These
drugs primarily target protein kinases, which catalyze
phosphorylation and regulate cellular processes like division,
metabolism, and apoptosis. Deregulation of protein kinases can lead
to cancer, as seen in colorectal cancer. Regorafenib is the only
approved kinase inhibitor for colorectal cancer treatment. To
expand the market, companies like F. Hoffmann-La Roche Ltd are
developing new kinase inhibitors, such as entrectinib, for
colorectal cancer treatment in Phase II clinical trials.
The colorectal cancer (CRC) therapeutics market is experiencing
significant trends in the regulatory scenario, with approvals for
new drugs like BRAFTOVI for BRAF V600E mutations and Mvasi, a
biosimilar for bevacizumab. Companies like Hutchmed, Akeda, and
Mirati Therapeutics are focusing on developing targeted therapies
for microsatellite instability-high (MSI-H) CRC, including
Fruquintinib and Krazati. An aging population and increasing
diagnosis rates lead to a high incidence of CRC, creating an unmet
need for effective treatments. Key players like Roche, Genentech,
and MSD are focusing on immunotherapies, such as Keytruda and
Tecentriq, for KRAS mutants and tolerable chemotherapies. The entry
of biosimilars and patent expiries may impact market dynamics,
while biomarker testing for mutations like NRAS and tolerability
remain critical factors for treatment selection. Thomas Wales, Oncology Analyst, predicts
continued growth in the CRC therapeutics market due to the high
incidence and unmet need.
Discover 360° analysis of this market. For
complete information, schedule your consultation - Book
Here!
Market Challenges
- According to the World Trade Organization's TRIPS agreement,
pharmaceutical companies are granted exclusive patent rights for 20
years from the date of application filing in the US and
Europe for their novel
therapeutics, including biologics. This allows companies to sell
these innovations at premium prices until patent expiration.
However, the loss of patents for therapeutics like AVASTIN
(bevacizumab), VECTIBIX (panitumumab), and ZALTRAP
(ziv-Aflibercept) in the colorectal cancer therapeutics market may
hamper its growth during the forecast period. Upon patent
expiration, biosimilars can enter the market, increasing
competition and potentially decreasing the price of the original
biologic therapeutics.
- The colorectal cancer therapeutics market faces several
challenges. With the aging population, incident cases are on the
rise. Mutation testing is crucial for effective treatment, but
patent expiries of key drugs like Cotellic and Fruquintinib
may impact sales. Targeted therapies, such as those for KRAS
mutations, present opportunities. However, tolerability issues and
serious adverse events, including discontinuation, limit their use.
Immunotherapies, like Keytruda and Tecentriq, offer potential, but
their high cost and limited efficacy against NRAS mutants pose
challenges. Biomarkers are essential for personalized treatment,
but their identification and availability remain an unmet need.
Companies like MSD, Genentech, Mirati Therapeutics, and others are
developing new treatments, including Tyrosine kinase inhibitors
like Krazati and Lumakras. The market is diverse, with Avastin,
Erbitux, Stivarga, and various chemotherapies available at
hospital, retail, and online pharmacies. Pipeline analysis is
crucial for understanding future trends. (Thomas Wales, Oncology Analyst)
For more insights on driver and
challenges - Request a sample report!
Segment Overview
This colorectal cancer therapeutics market report extensively
covers market segmentation by
- Type
- 1.1 Targeted therapy
- 1.2 Immunotherapy
- 1.3 Chemotherapy
- Geography
- 2.1 North America
- 2.2 Europe
- 2.3 Asia
- 2.4 Rest of World (ROW)
1.1 Targeted therapy- The colorectal cancer
therapeutics market is witnessing significant growth due to the
increasing prevalence of colorectal cancer and the development of
new treatment options. Key players in the market include Pfizer,
Merck, and Roche. These companies are investing in research and
development to launch innovative therapies, such as targeted drugs
and immunotherapies. The market is expected to continue expanding
due to the rising demand for effective treatments and improving
healthcare infrastructure.
For more information on market segmentation with geographical
analysis including forecast (2024-2028) and historic data
(2017-2021) - Download a Sample Report
Research Analysis
Colorectal cancer, also known as colon or rectal cancer, is a
type of gastrointestinal malignancy that affects the colon or
rectum. Colorectal adenocarcinoma is the most common type,
accounting for over 90% of cases. Gastrointestinal carcinoid tumors
are less common but can also develop in the colorectal region.
According to Dana-Farber Cancer Institute, young onset colorectal
cancer is on the rise, particularly in those under 50 years old.
Targeted therapies, such as Avastin, Erbitux, Stivarga, and
immunotherapies like Keytruda, are increasingly being used to treat
colorectal cancer. Hospital pharmacies, retail pharmacies, and
online pharmacies play a crucial role in the distribution of these
therapies. The aging population and increased diagnosis rates have
led to a significant increase in incident cases of colorectal
cancer. Mutation testing is essential for determining the best
treatment approach, with KRAS being a common mutation in colorectal
cancer. Patent expiries and market competition are influencing the
landscape, with Thomas Wales,
Oncology Analyst, predicting a shift towards biosimilars and
generics. MSD, Genentech, and other key players are investing in
new immunotherapies and tyrosine kinase inhibitors to stay
competitive.
Market Research Overview
Colorectal cancer, also known as colon or rectal cancer, is a
major health concern worldwide, with colorectal adenocarcinoma
being the most common type. Gastrointestinal carcinoid tumors are
less common but can also develop in the colon or rectum. The
Dana-Farber Cancer Institute and other research organizations are
working on new treatments for YoungOnset Colorectal Cancer.
Targeted therapies, such as Avastin (bevacizumab), Erbitux
(cetuximab), Stivarga (regorafenib), and immunotherapies like
Keytruda (pembrolizumab) and Immunotherapies (nivolumab), are
transforming colorectal cancer treatment. These therapies, which
include BRAFTOVI (encorafenib) for BRAF V600E mutations, are
administered through hospital pharmacies, retail pharmacies, and
online pharmacies. Pipeline analysis reveals numerous potential
treatments in development, including drugs targeting tyrosine
kinase, microsatellite instability, and KRAS mutations from
companies like Akeda Therapeutics, Hutchmed, Roche, Mirati
Therapeutics, and MSD. The regulatory scenario is favorable, with
the National Library of Medicine and CRC (Colorectal Cancer)
databases providing valuable information. Aging population,
diagnosis rates, and incident cases continue to rise, creating an
unmet need for effective, tolerable treatments. Mutation testing
and biomarkers play crucial roles in identifying the most effective
therapies for each patient. However, serious adverse events,
discontinuation due to intolerability, and the impact of patent
expiries on drug prices are significant challenges. Thomas Wales, Oncology Analyst, provides
insights into these issues and more. Chemotherapies containing
5-FU, oxaliplatin, and irinotecan remain essential treatments, but
their serious adverse events and discontinuation rates necessitate
the development of new, more effective options. NRAS mutants and
other challenging patient populations require innovative
approaches. In summary, the colorectal cancer therapeutics market
is rapidly evolving, with a focus on targeted therapies,
immunotherapies, and personalized medicine. Challenges include an
aging population, unmet need, and the impact of patent expiries on
drug prices. Ongoing research and regulatory support are crucial
for advancing the field and improving patient outcomes.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
- Type
-
- Targeted Therapy
- Immunotherapy
- Chemotherapy
- Geography
-
- North America
- Europe
- Asia
- Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory
company. Their research and analysis focuses on emerging market
trends and provides actionable insights to help businesses identify
market opportunities and develop effective strategies to optimize
their market positions.
With over 500 specialized analysts, Technavio's report library
consists of more than 17,000 reports and counting, covering 800
technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100
Fortune 500 companies. This growing client base relies on
Technavio's comprehensive coverage, extensive research, and
actionable market insights to identify opportunities in existing
and potential markets and assess their competitive positions within
changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/colorectal-cancer-therapeutics-market-size-is-set-to-grow-by-usd-2-00-billion-from-2024-2028--increasing-geriatric-population-boost-the-market-technavio-302214520.html
SOURCE Technavio